Cure My Disease

Don't miss your cure!

 Log in / Sign up

A special MRI peers into the chemistry of hearts and brains in diabetes

NCT ID NCT07820722

Knowledge-focused Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

People with type 2 diabetes often have high lactate levels, which researchers link to heart failure and thinking problems. This early study uses a carbon-13 MRI contrast agent called hyperpolarized pyruvate to watch how the heart and brain process pyruvate, lactate, and bicarbonate. Researchers scan 32 adults with type 2 diabetes before and after treatment with semaglutide to see whether the scans can detect metabolic changes. The contrast agent is experimental and not approved for general use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperpolarized carbon-13 pyruvate, an experimental MRI contrast agent
What this could lead to
If the imaging works, doctors could one day use it to see how diabetes changes heart and brain chemistry and to judge whether treatments such as semaglutide are helping.
What could go wrong
This is a very early, small imaging study with 32 participants. It tests whether the scans produce useful pictures, not whether any treatment works, and the contrast agent is not approved for general use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult participants of all ethnic groups/race categories (≥ 18 years of age) * Blood lactate ≥ 2 mmol/L ≤ 5 mmol/L * Blood pressure target \< 130/80 * No history of macrovascular or microvascular disease * For participants in Groups 1 and 2: Prescribed a semaglutide dose of 0.5 mg S/C weekly * For participants in Groups 3 and 4: HbA1c between 7-9% on evidence-based medications as per the Diabetes Canada guidelines, but not GLP-1RA semaglutide * Written informed consent Exclusion Criteria: * History of macrovascular or microvascular disease * Automatic implantable cardiac-defibrillators (AICD) or pacemaker, either at time of study or required within 3 months of the study * Participants on anticonvulsants, benzodiazepines, immunosuppressants and/or antiarrhythmics * Any clinically significant or unstable medical condition that might limit their ability to complete the study * Any malignancy not considered cured, except basal cell carcinoma of the skin * Body mass index greater than 40.0 * Claustrophobia and/or inability to undergo MRI without sedation * Contraindications to MRI as indicated on the standard MRI safety screening questionnaire * Participant declines or is unable to

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.